Anti-IL12Rbeta1 Antibodies And Their Use In Treating Autoimmune And Inflammatory Disorders

摘要

The present invention relates to antibodies that specifically bind to IL12Rβ1, the non-signal transducing chain of both the heterodimeric IL12 and IL23 receptors. The invention more specifically relates to specific antibodies that are IL12 and IL23 receptor antagonists capable of inhibiting IL12/IL18 induced IFNγproduction of blood cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting IFNγproduction, IL12 and/IL23 signaling, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders.